Direct application of XXXX for the treatment of @entity102 .

@entity1 @entity2172 @entity102 @entity134 @entity619
We undertook a prospective study to determine the safety and effectiveness of the direct administration of a @entity134 to the eustachian tube via the Silverstein MicroWick in 11 @entity1 with @entity102 , including two who had Samter's triad. All @entity1 had previously been treated with medical therapy and surgical @entity2172 without resolution. The MicroWick was placed directly in the eustachian tube orifice through a pressure-equalization tube. @entity1 received 3 drops of @entity619 4 mg/ml three times a day. The drops were discontinued after 4 weeks, and the MicroWick and ventilation tube were removed after 3 months. At study's end, eight @entity1 (72.7%) reported subjective improvement in terms of a reduction in aural pressure and fullness. Audiometric testing demonstrated a 55% reduction in the mean air-bone gap and a 3% increase in the mean speech discrimination score. Bone pure-tone averages remained stable. Tympanometry showed that five @entity1 (45.5%) converted from type B or C tympanograms to type A. Four @entity1 (36.4%) had persistent perforations. Both @entity1 with Samter's triad improved with therapy. These preliminary results suggest that direct @entity619 administration to the eustachian tube is safe and effective for the treatment of @entity102 . Long-term studies to confirm these findings are under way.
